|
|
Application effect of Levonorgestrel Intrauterine Contraceptive System combined with Didroxyprogesterone in adenomyosis |
PAN Hong1 LI Yuan2 LIN Hong1 HUANG Xiaoping1 |
1. Department of Obstetrics and Gynecology, Yichun People′s Hospital, Jiangxi Province, Yichun 336000, China;
2. Department of Obstetrics and Gynecology, People′s Hospital of Wanzai County, Jiangxi Province, Wanzai 336199, China |
|
|
Abstract Objective To investigate the application effect of Levonorgestrel Intrauterine Contraceptive System with Didroxyprogesterone in adenomyosis (AM). Methods A total of 70 cases of AM patients from the Department of Obstetrics and Gynecology of Yichun People′s Hospital from January 2019 to December 2021 were selected as the study subjects, and they were divided into the study group and the control group, with 35 cases in each group. The patients in the control group were treated with Levonorgestrel Intrauterine Contraceptive System, and the patients in the study group were treated with Levonorgestrel Intrauterine Contraceptive System combined with Didroxyprogesterone. The menstrual situation, uterine situation, sex hormone level, the rate of drip bleeding and accidental exfoliation and the total effective rate were compared between the two groups before and after treatment. Results Before treatment, there were no significant differences in the menstrual volume, pain degree, endometrial thickness and uterine volume between the two groups (P>0.05). The menstrual volume of the study group after treatment was less than that of the control group, the degree of pain of the study group after treatment was less than that of the control group, and the endometrial thickness and uterine volume of the study group after treatment were less than those of the control group, the differences were statistically significant (P<0.05). Before treatment, there were no significant differences in the levels of luteinizing hormone (LH), serum follicle stimulating hormone (FSH) and estradiol (E2) between the two groups (P>0.05). The level of E2 of the study group after treatment was higher than that of the control group, the difference was statistically significant (P<0.05). The drip bleeding rate and the accidental shedding rate in the study group were lower than those in the control group, the differences were statistically significant (P<0.05). The total effective rate of the study group was higher than that of the control group, the difference was statistically significant (P<0.05). Conclusion Levonorgestrel Intrauterine Contraceptive System combined with Didroxyprogesterone was effective in treating AM, which can effectively improve the clinical symptoms, prevent adverse events and improve the quality of life.
|
|
|
|
|
[1] |
陈行,于传鑫.米非司酮联合地屈孕酮片序贯治疗子宫腺肌症研究[J].中国妇幼健康研究,2019,30(12):1515-1519.
|
[2] |
吴晓虹,张文杰,武冬娜.子宫腺肌病患者采用曼月乐联合小剂量米非司酮治疗的效果及对血清神经生长因子可溶性CD147血管内皮生长因子水平变化的影响[J].河北医学,2019,25(1):50-54.
|
[3] |
肖勇,唐莉菲,纪燕琴.左炔诺酮宫内缓释系统及其联合促性腺激素释放激素激动剂治疗子宫腺肌病的临床对照研究[J].临床医学工程,2019,26(7):907-908.
|
[4] |
谢幸,苟文丽.妇产科学[M].北京:人民卫生出版社,2013:45.
|
[5] |
张笑飞,王金丽.米非司酮联合地屈孕酮治疗子宫腺肌症对子宫体积、痛经症状积分及月经的影响[J].中国高等医学教育,2020,(11):146,封3.
|
[6] |
郑文娟.小剂量米非司酮治疗子宫腺肌症的疗效和不良反应分析[J].中国医药指南,2018,16(7):27-28.
|
[7] |
黄益辉,李萍.曼月乐节育环对治疗子宫腺肌症患者月经过多的疗效及对血清CA125的影响分析[J].首都食品与医药,2019,26(11):10-11.
|
[8] |
汤芝丽.小剂量米非司酮联合地屈孕酮片对子宫腺肌症患者子宫体积及痛经程度的影响[J].中国基层医药,2020,27(18):2264-2268.
|
[9] |
刘群英,黄文静,胡庆兰,等.腹腔镜下子宫腺肌病病灶切除术后应用GnRH-a联合曼月乐治疗的疗效分析[J].中国处方药,2020,18(8):142-144.
|
[10] |
华欢欢,王天泰.曼月乐环治疗子宫腺肌病62例临床观察[J].世界最新医学信息文摘(连续型电子期刊),2018, 18(21):100,109.
|
[11] |
张静,张宁芝,陈洁,等.地屈孕酮片联合拜阿司匹林对薄型子宫内膜不孕患者子宫内膜厚度及性激素的影响[J].中国临床药理学杂志,2019,35(12):2751-2753,2763.
|
[12] |
杨琳.GnRH-a联合曼月乐对子宫腺肌病患者疼痛程度及月经量评分的影响[J].当代医学,2021,27(5):109-111.
|
[13] |
杨亚莉.宫腔镜子宫内膜切除术联合左炔诺孕酮宫内缓释系统治疗子宫腺肌病疗效观察[J].实用中西医结合临床,2019,19(1):96-97,153.
|
[14] |
吴亚玲,李合欣.左炔诺孕酮宫内缓释系统治疗子宫腺肌症195例临床分析[J].中国药物与临床,2018,18(3):454-455.
|
[15] |
付虹,张丽萍.米非司酮联合宫瘤消胶囊治疗子宫腺肌症的临床效果观察[J].中国医药,2018,13(3):440-442.
|
|
|
|